Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1349-1355

  Liu, Tiancheng ^a   Jabbes, Mohamed ^a   Nedrow Byers, Jessie R ^a   Wu, Lisa Y ^a   Bryan, Jeffrey N ^a   Berkman, Clifford E ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Cancer Targeted Technology   (United States)

Author keywords

Breast cancer; Human umbilical vein endothelial cells; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BREAST TUMOR; CANCER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBENDOTHELIUM; TUMOR CONDITIONED MEDIUM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIGENS, SURFACE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955046670     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.946     Document Type: Article

References (39)

1. Ghosh A and Heston WD: Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91: 528-539, 2004.
2. Tagawa ST, Beltran H, Vallabhajosula S, et al: Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116: 1075-1083, 2010.
3. Bander NH: Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3: 216-225, 2006.
4. Nanus DM, Milowsky MI, Kostakoglu L, et al: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170: S84-S89, 2003. (Pubitemid 37413948)
5. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5: 2674-2681, 1999. (Pubitemid 29493938)
6. Haffner MC, Kronberger IE, Ross JS, et al: Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40: 1754-1761, 2009.
7. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-3198, 1999. (Pubitemid 29316022)
8. Liu H, Moy P, Kim S, et al: Monoclonal antibodies to the extra-cellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634, 1997. (Pubitemid 27381196)
9. Milowsky MI, Nanus DM, Kostakoglu L, et al: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25: 540-547, 2007. (Pubitemid 350002961)
10. Morris MJ, Pandit-Taskar N, Divgi CR, et al: Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 13: 2707-2713, 2007. (Pubitemid 46788039)
11. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS and Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58: 4787-4789, 1998. (Pubitemid 28503668)
12. Carter RE, Feldman AR and Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-753, 1996. (Pubitemid 26041162)
13. Pinto JT, Suffoletto BP, Berzin TM, et al: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445-1451, 1996. (Pubitemid 126447436)
14. Mesters JR, Henning K and Hilgenfeld R: Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr 63: 508-513, 2007. (Pubitemid 46465946)
15. Davis MI, Bennett MJ, Thomas LM and Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 102: 5981-5986, 2005. (Pubitemid 40594241)
16. Mesters JR, Barinka C, Li W, et al: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25: 1375-1384, 2006.
17. Wu LY, Anderson MO, Toriyabe Y, et al: The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 15: 7434-7443, 2007. (Pubitemid 47539133)
18. Ding P, Helquist P and Miller MJ: Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors. Org Biomol Chem 5: 826-831, 2007.
19. Majer P, Hin B, Stoermer D, et al: Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J Med Chem 49: 2876-2885, 2006.
20. Aggarwal S, Singh P, Topaloglu O, Isaacs JT and Denmeade SR: A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 66: 9171-9177, 2006. (Pubitemid 44521137)
21. Wone DW, Rowley JA, Garofalo AW and Berkman CE: Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg Med Chem 14: 67-76, 2006. (Pubitemid 41635469)
22. Zhou J, Neale JH, Pomper MG and Kozikowski AP: NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 4: 1015-1026, 2005.
23. Tsukamoto T, Wozniak KM and Slusher BS: Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 12: 767-776, 2007. (Pubitemid 47362787)
24. Liu T, Toriyabe Y, Kazak M and Berkman CE: Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 47: 12658-12660, 2008.
25. Liu T, Wu LY, Hopkins MR, Choi JK and Berkman CE: A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20: 7124-7126, 2010.
26. Liu T, Wu LY, Kazak M and Berkman CE: Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68: 955-964, 2008. (Pubitemid 351794160)
27. Liu T, Wu LY, Choi JK and Berkman CE: In vitro targeted photodynamic therapy with a pyropheophorbide - a conjugated inhibitor of prostate-specific membrane antigen. Prostate 69: 585-594, 2009.
28. Lapi SE, Wahnishe H, Pham D, et al: Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 50: 2042-2048, 2009.
29. Hillier SM, Maresca KP, Femia FJ, et al: Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 69: 6932-6940, 2009.
30. Kularatne SA, Wang K, Santhapuram HK and Low PS: Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 6: 780-789, 2009.
31. Liu T, Wu LY, Choi JK and Berkman CE: Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol 36: 777-784, 2010.
32. Anderson MO, Wu LY, Santiago NM, et al: Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 15: 6678-6686, 2007. (Pubitemid 47385247)
33. Maung J, Mallari JP, Girtsman TA, et al: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 12: 4969-4979, 2004. (Pubitemid 39164405)
34. Marchetti M, Vignoli A, Russo L, et al: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 121: 637-645, 2008. (Pubitemid 351305285)
35. Zhang L, Wang CY, Yang R, et al: Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 26: 634-640, 2008.
36. Chang X, Han J, Pang L, Zhao Y, Yang Y and Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 9: 40, 2009.
37. Troyer JK, Beckett ML and Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30: 232-242, 1997. (Pubitemid 27172834)
38. Wang XY, Tan JX, Vasse M, Delpech B and Ren GS: Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J (Engl) 122: 1300-1304, 2009.
39. Conway RE, Petrovic N, Li Z, Heston W, Wu D and Shapiro LH: Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26: 5310-5324, 2006. (Pubitemid 44036201)